Endo plunks down $637M for Indevus

Endo Pharmaceuticals says it will be acquiring Indevus Pharmaceuticals for $370 million in cash and an additional $267 in future payouts, in an effort to move away from the pain-management business and into more-lucrative therapeutic areas with a less competition. Release

Suggested Articles

It’s final: England won’t be covering AZ’s quick-selling Tagrisso in previously untreated non-small cell lung cancer patients with EGFR mutatations.

Top J&J meds have managed to hang onto market share in the face of new generics and biosims, but the drugmaker expects the pain to continue in 2020.

Lonza’s search for a new CEO is expected to be wrapped up this year as the CDMO homes in on a list of veterans from outside the company.